Ashwagandha And Stress Biomarker Research

Last updated: October 4, 2026 - Reviewed by Verdant Wellness Editorial Team

---

Table of Contents

• What Are Stress Biomarkers And Why Do They Matter?
• How Ashwagandha Interacts With The HPA Axis
• Cortisol: The Primary Ashwagandha Stress Biomarker
• Salivary Cortisol Versus Serum Cortisol In Ashwagandha Trials
• Inflammatory Biomarkers: Ashwagandha CRP and hsCRP Evidence
• Ashwagandha And HRV: An Emerging Stress Indicator
• KSM-66 Cortisol Biomarker Data: What The Trials Show
• How Fast Do Stress Biomarkers Respond?
• Dose And Extract Type: What Clinical Trials Actually Used
• Does Ashwagandha Work Better In Stressed Adults?
• Meta-Analyses And Systematic Reviews: 2024–2026 Update
• Safety, Side Effects, And Long-Term Biomarker Monitoring
• Practical Takeaways For Interpreting The Evidence
• Frequently Asked Questions

---

Introduction

If you search for natural approaches to managing chronic stress, ashwagandha (Withania somnifera) almost certainly appears near the top of your results. But popular wellness coverage tends to focus on how ashwagandha feels — the subjective sense of calm, the better sleep, the reduced anxiety. What receives far less attention is the underlying question that scientists actually care about: What does ashwagandha do to measurable biological indicators of stress?

That question sits at the intersection of biomarker science and botanical pharmacology, and it has generated a growing body of clinical trial data over the past decade. This post examines that data closely — the study designs, the numbers, the limitations, and the most recent findings from 2024 through 2026. Whether you are a clinician evaluating the evidence, a researcher reviewing the literature, or a health-conscious individual trying to separate signal from noise, this is a comprehensive look at ashwagandha and stress biomarker research as it currently stands.

---

---

What Are Stress Biomarkers And Why Do They Matter?

A biomarker, in its broadest definition, is any measurable biological characteristic that reflects a physiological or pathological process. Stress biomarkers specifically are molecules or physiological signals whose concentrations or patterns change in response to acute or chronic psychological and physiological stress.

The Core Categories

Hormonal biomarkers are the most studied in the context of adaptogens. Cortisol — produced by the adrenal cortex in response to signals from the hypothalamic-pituitary-adrenal (HPA) axis — is considered the primary biomarker of stress in human research. It can be measured in serum, saliva, urine, and even hair (reflecting cumulative exposure over months). Dehydroepiandrosterone sulfate (DHEA-S), another adrenal hormone, is sometimes measured alongside cortisol because the cortisol-to-DHEA-S ratio may reflect the balance of the stress response rather than cortisol alone.

Inflammatory biomarkers include C-reactive protein (CRP), high-sensitivity CRP (hsCRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). Chronic psychological stress is a well-established driver of low-grade systemic inflammation. Because ashwagandha contains withanolides with documented anti-inflammatory properties in preclinical research, these markers are increasingly included in clinical ashwagandha biomarker studies.

Autonomic nervous system markers include heart rate variability (HRV), a non-invasive measure of the balance between sympathetic and parasympathetic nervous system activity. Lower HRV is associated with higher allostatic load and reduced stress resilience. HRV is beginning to appear in ashwagandha trials as a functional biomarker of the stress response.

Psychometric scales — the Perceived Stress Scale (PSS), the General Health Questionnaire (GHQ-28), the Depression Anxiety Stress Scales (DASS), and others — are technically patient-reported outcomes rather than biological biomarkers, but they are routinely reported alongside biological measurements in the same trials. Understanding how biological and subjective measures correlate (or fail to correlate) is one of the more interesting questions in this research space.

Why Biomarkers Matter More Than Self-Report Alone

Self-reported stress is subject to placebo effects, response bias, and expectation. A participant who believes they are taking an effective supplement may report feeling less stressed regardless of any actual physiological change. Measurable biomarkers like serum cortisol provide an objective anchor for these subjective reports — and sometimes, as we will see, the objective and subjective data tell meaningfully different stories.

---

How Ashwagandha Interacts With The HPA Axis

To understand why ashwagandha stress biomarkers are studied in the first place, you need to understand the HPA axis and what an adaptogen is theorized to do.

The HPA Axis In Brief

When the brain perceives stress, the hypothalamus releases corticotropin-releasing hormone (CRH). CRH signals the pituitary gland to release adrenocorticotropic hormone (ACTH). ACTH travels through the bloodstream to the adrenal glands, which then produce and release cortisol. Under normal conditions, cortisol feeds back to the hypothalamus and pituitary to shut down this cascade — a negative feedback loop. Under chronic stress, this feedback can become dysregulated, resulting in persistently elevated cortisol, blunted diurnal variation, or, in some cases, a flattened or hypocortisolemic pattern.

The Adaptogen Framework

The concept of an adaptogen — a substance that non-specifically increases resistance to stress — was first formalized by Soviet pharmacologist Nikolai Lazarev in 1947 and later expanded by Israel Brekhman. An ideal adaptogen, under this framework, should normalize physiological responses to stress rather than simply suppress or stimulate them. This means it should lower cortisol when cortisol is chronically elevated and potentially support adrenal function when it is depressed.

Ashwagandha is classified as an adaptogen in Ayurvedic medicine, where it has been used for over 3,000 years as a rasayana (rejuvenating tonic). Modern research has identified withanolides — steroidal lactones unique to Withania somnifera — as likely bioactive compounds, though the full mechanism of action involves multiple pathways including GABA-A receptor modulation, thyroid axis interactions, and direct effects on inflammatory signaling.

Proposed Mechanisms Relevant To Biomarkers

1. Cortisol modulation via HPA feedback enhancement: Withanolides may enhance glucocorticoid receptor sensitivity, improving the negative feedback signal that tells the HPA axis to reduce cortisol production.
2. NF-κB pathway inhibition: Withaferin A, one of the most studied withanolides, inhibits NF-κB signaling, which is a central driver of inflammatory cytokine production — directly relevant to ashwagandha inflammatory markers.
3. Cholinergic and GABAergic activity: These pathways modulate the autonomic nervous system, which may explain potential effects on HRV.

A 2026 PMC review on the endocrine effects of ashwagandha summarized trial evidence suggesting that ashwagandha may attenuate HPA-axis activity and reduce fasting morning cortisol and DHEA-S in some participants, though with variability across populations.

---

Cortisol: The Primary Ashwagandha Stress Biomarker

Cortisol is unquestionably the most-studied ashwagandha stress biomarker in the clinical literature. Let us examine the individual trial data before turning to meta-analytic summaries.

Key Individual Trials

The Chandrasekhar 2012 Trial (64 Adults, 60 Days)

One of the most cited ashwagandha biomarker studies was published in the Indian Journal of Psychological Medicine. In this randomized, double-blind, placebo-controlled trial, 64 adults with a history of chronic stress were randomized to receive either 300 mg of ashwagandha root extract twice daily or placebo for 60 days. The ashwagandha group showed a 27.9% reduction in serum cortisol from baseline, a finding that is now widely cited in both clinical and popular literature. Importantly, this trial also documented significant improvements in all four primary stress and anxiety rating scales used, suggesting that the biological and subjective effects moved in the same direction.

The 61-Adult Randomized Trial

A separate 60-day randomized placebo-controlled study in 61 adults provides additional granularity in the cortisol data. In the ashwagandha sustained-release group, serum cortisol fell from 9.04 ± 3.77 µg/dL to 6.34 ± 2.31 µg/dL — a reduction of approximately 2.7 µg/dL. Significant reductions were also documented on the PSS, GHQ-28, and DASS scales, reinforcing the coherence between hormonal and psychometric outcomes in this population.

The 2026 Three-Arm Placebo-Controlled Trial (141 Adults, 8 Weeks)

This more recent and methodologically rigorous trial enrolled 141 adults across three arms, testing two different ashwagandha formulations against placebo. The ashwagandha arms showed mean serum cortisol reductions of −2.78 µg/dL and −2.55 µg/dL, compared with −1.10 µg/dL in the placebo group. These are directionally consistent with earlier findings. However — and this is clinically important — the between-group differences did not reach statistical significance. This does not mean the effect is absent, but it means this trial alone cannot confirm that the cortisol reduction was attributable to the intervention rather than natural variation, regression to the mean, or the active placebo response.

Interpreting The Cortisol Data

Several nuances deserve emphasis when reviewing individual ashwagandha biomarker study data:

Baseline cortisol matters enormously. Participants who enter trials with elevated baseline cortisol — reflecting chronic stress, poor sleep, or metabolic dysfunction — consistently show larger absolute reductions than participants who are normocortisolemic at baseline. This is consistent with the adaptogen hypothesis that effects are more pronounced when the system is dysregulated.

Measurement timing matters. Cortisol follows a steep diurnal rhythm, peaking in the early morning and falling throughout the day. Studies that measure cortisol at different clock times, or that fail to standardize collection timing, produce results that are difficult to compare directly.

Statistical significance versus clinical significance. A reduction of 2–3 µg/dL in serum cortisol may or may not be clinically meaningful depending on the starting value, the individual's symptom burden, and what downstream effects — on sleep, immune function, metabolic health — accompany that reduction.

---

---

Salivary Cortisol Versus Serum Cortisol In Ashwagandha Trials

A technically important distinction in ashwagandha cortisol saliva versus serum research is how the biofluid used for cortisol measurement affects both the data and its interpretation.

Why Salivary Cortisol Is Used

Salivary cortisol reflects the free (unbound) fraction of the hormone, which is biologically active and not subject to the variability introduced by changes in cortisol-binding globulin (CBG). Blood draw procedures also induce acute stress responses that can transiently elevate serum cortisol, a confound that salivary collection avoids. Ashwagandha cortisol saliva studies use passive drool collection protocols or cotton roll devices (Salivettes), and participants are typically instructed to avoid food, drink, and exercise before collection.

Serum Cortisol: The More Commonly Used Measure

Despite the theoretical advantages of saliva, the majority of ashwagandha biomarker study designs have used serum cortisol — likely because venous blood collection was already required for other biochemical panels (lipids, thyroid hormones, complete blood count) included as secondary outcomes. This means that most of the published data on ashwagandha and cortisol reduction comes from total serum cortisol measurements.

Emerging Use Of Salivary And Multi-Point Sampling

More recent trial designs are moving toward multi-timepoint cortisol sampling to assess the cortisol awakening response (CAR) — the rapid rise in cortisol in the 30–45 minutes after waking — as a more sensitive marker of HPA axis regulation. The CAR is blunted in chronically stressed individuals and may normalize with effective interventions. Although the published ashwagandha literature has not yet extensively characterized CAR changes, this is an area of methodological development that future ashwagandha biomarker study designs are likely to address.

---

Inflammatory Biomarkers: Ashwagandha CRP and hsCRP Evidence

While cortisol dominates the ashwagandha stress biomarker conversation, there is a growing body of evidence examining ashwagandha's effects on inflammatory markers — and for good reason. The link between psychological stress and systemic inflammation is well established through multiple pathways, including glucocorticoid resistance of immune cells, sympathetic nervous system activation of pro-inflammatory signaling, and alterations in gut microbiome composition.

Ashwagandha And CRP

C-reactive protein is an acute-phase protein produced by the liver in response to inflammatory signaling, particularly IL-6. It is one of the most commonly measured ashwagandha inflammatory markers in clinical trials because it is inexpensive, standardized across laboratories, and robustly associated with cardiovascular and metabolic risk.

Several trials that were primarily designed to measure cortisol also collected CRP as a secondary endpoint. The direction of effect has generally been toward CRP reduction in ashwagandha groups, particularly in participants with elevated baseline values. However, the magnitude of reduction has been modest in most reports, and many studies were not powered to detect significant changes in CRP specifically.

Ashwagandha hsCRP: High-Sensitivity Measurement

Ashwagandha hsCRP studies use a more sensitive assay that can detect low-grade inflammation even when standard CRP assays return values below the conventional detection threshold. This is particularly relevant for the stress-inflammation connection because chronically stressed but otherwise healthy adults often show subclinical elevations — in the 1–3 mg/L range — that standard CRP measurement misses but that carry meaningful cardiovascular risk over time.

The preclinical rationale for ashwagandha hsCRP effects is strong. In cell culture and animal models, withaferin A has demonstrated potent NF-κB inhibition and reductions in multiple pro-inflammatory cytokines. Translating this to human serum hsCRP changes requires larger trials with inflammatory biomarkers as primary endpoints rather than secondary afterthoughts — and these trials are beginning to appear in the literature.

Ashwagandha Inflammatory Markers Beyond CRP

Some ashwagandha biomarker studies have measured broader panels of ashwagandha inflammatory markers including:

• IL-6: An upstream driver of CRP production and a cytokine with direct effects on mood, fatigue, and cognitive function.
• TNF-α: A master regulator of inflammatory signaling that is elevated in chronic stress states.
• Malondialdehyde (MDA) and superoxide dismutase (SOD): Markers of oxidative stress, which often accompanies inflammatory activation.

Evidence for ashwagandha effects on these markers is more preliminary than for cortisol, but the overall pattern from available studies suggests a broad anti-inflammatory and antioxidant profile consistent with the withanolide mechanisms described earlier. As with cortisol, effect sizes tend to be larger in populations with elevated baseline inflammation.

---

Ashwagandha And HRV: An Emerging Stress Indicator

Heart rate variability is a measure of the variation in time between consecutive heartbeats. Contrary to intuition, a higher HRV indicates a healthier, more flexible autonomic nervous system — one that can shift rapidly between sympathetic (fight-or-flight) and parasympathetic (rest-and-digest) states. Chronic stress, sleep deprivation, and poor metabolic health all reduce HRV, making it a functionally meaningful biomarker of resilience.

The Ashwagandha HRV Literature

Ashwagandha HRV research is more limited than cortisol research in terms of the number of published trials, but the evidence is promising. The proposed mechanism involves ashwagandha's GABAergic and cholinergic effects, which would increase parasympathetic tone and therefore improve HRV metrics such as root mean square of successive differences (RMSSD) and high-frequency (HF) power.

Several trials that used wearable devices or ECG-based HRV measurement alongside hormonal biomarkers have reported improvements in HRV metrics in ashwagandha groups relative to placebo. These findings position ashwagandha HRV effects as a functionally relevant complement to the cortisol data — suggesting that the intervention may shift the autonomic balance toward greater parasympathetic dominance rather than simply reducing adrenocortical output.

HRV As A Population-Sensitive Biomarker

One important feature of ashwagandha HRV research is that HRV effects, like cortisol effects, appear more pronounced in populations with compromised baseline autonomic function. Athletes under high training loads, individuals with occupational stress, and adults with sleep disorders all show more substantial HRV improvements than low-stress control populations — again consistent with the adaptogen framework of normalizing dysregulated physiology.

---

KSM-66 Cortisol Biomarker Data: What The Trials Show

KSM-66 is a proprietary full-spectrum ashwagandha root extract manufactured by Ixoreal Biomed and standardized to a minimum of 5% withanolides using a patented extraction process that preserves the natural balance of the root's active constituents. It is one of the most extensively studied ashwagandha extracts in the clinical literature, and a significant proportion of the published KSM-66 stress markers data comes from randomized controlled trials.

Why Extract Standardization Matters For Biomarker Research

Before examining the specific KSM-66 cortisol biomarker data, it is worth understanding why the choice of extract matters for biomarker research. Ashwagandha root and leaf preparations vary substantially in their withanolide content and profile. Leaf-based extracts tend to be richer in withaferin A, which has potent but potentially cytotoxic effects at higher concentrations. Root-based extracts emphasize withanolides that are more specifically associated with adaptogenic and anti-stress effects.

KSM-66 stress indicators research benefits from the fact that the extract is fully characterized, allowing dose-response relationships to be established and results to be compared across independent trials using the same preparation.

Clinical Trial Evidence Specific To KSM-66

The 64-adult, 60-day trial that demonstrated the 27.9% cortisol reduction used a root extract that has been associated with KSM-66 in subsequent reviews and summaries. KSM-66 stress markers trials have also measured DHEA-S, testosterone, and thyroid hormones as secondary biomarkers, finding directionally positive but variable effects.

The 61-adult trial showing cortisol reduction from 9.04 µg/dL to 6.34 µg/dL also used a standardized root extract consistent with the KSM-66 profile. The KSM-66 cortisol biomarker findings across these trials support a consistent pattern: in adults with elevated baseline cortisol and documented stress, standardized ashwagandha root extract at doses of 300–600 mg/day for 60 days reduces serum cortisol by approximately 2–3 µg/dL, or roughly 20–30% from baseline.

KSM-66 Stress Indicators Beyond Cortisol

KSM-66 stress indicators research has also documented effects on:

• Psychometric stress scales (PSS, GHQ-28, DASS) showing significant improvements versus placebo
• Sleep quality measured by actigraphy and validated questionnaires
• Cardiorespiratory endurance in athletic populations
• Cognitive function including memory, reaction time, and executive function

These outcomes are relevant to stress biomarker interpretation because they suggest the cortisol changes are accompanied by functionally meaningful improvements in stress-related domains — not merely a biochemical shift without phenotypic consequence.

---

---

How Fast Do Stress Biomarkers Respond?

One of the most common practical questions about ashwagandha biomarker evidence is how quickly measurable changes in cortisol, CRP, or HRV can be expected to appear. The clinical trial data provides some guidance, though the answer varies by biomarker type and population.

Cortisol: Timeline Evidence

The majority of published ashwagandha biomarker study designs have measured cortisol at baseline and at 60 days, with fewer trials including intermediate timepoints. From the available data:

• At 4 weeks: Some trials with intermediate measurements have reported directional cortisol reductions, but these tend to be smaller in magnitude than 8-week reductions and less consistently significant.
• At 8 weeks: This is the timepoint at which the most robust and consistent cortisol reductions have been documented. The 2026 BJPsych Open meta-analysis specifically identified 8-week outcomes as showing statistically significant reductions in both perceived stress and cortisol.
• At 12 weeks: Fewer trials extend to this duration, but those that do suggest that effects are maintained rather than diminishing.

Inflammatory Markers: Potentially Slower Response

Ashwagandha CRP and hsCRP changes, where measured, may require longer intervention periods to manifest as statistically detectable reductions. CRP is highly variable day-to-day and responds to multiple lifestyle factors simultaneously, which means the signal-to-noise ratio for detecting supplement effects is lower than for cortisol.

HRV: Potentially Faster Response

Ashwagandha HRV improvements may emerge more quickly than cortisol reductions because autonomic regulation is highly responsive to acute changes in stress perception, sleep quality, and physical recovery — all of which ashwagandha may influence simultaneously. Some ashwagandha HRV studies have reported measurable improvements at 4–6 weeks.

The Practical Implication

The evidence base suggests that 8 weeks at an adequate dose represents a reasonable minimum intervention period for detecting meaningful changes in serum cortisol in stressed adults. Shorter trials may underestimate the effect size, and individuals evaluating their own response should account for the biological latency before drawing conclusions.

---

Dose And Extract Type: What Clinical Trials Actually Used

The clinical literature on ashwagandha stress biomarkers spans a range of doses, extract types, and delivery formats. Understanding what was actually used in trials — rather than what is marketed — is essential for interpreting the evidence correctly.

Dose Range In Published Trials

• 250 mg/day: Used in some trials, including a 2024 study examining ashwagandha combined with meditation. Significant cortisol reductions were reported even at this lower dose.
• 300 mg/day: The most commonly studied single-dose level. The 64-adult 60-day trial used 300 mg twice daily (600 mg total). Some trials used 300 mg once daily.
• 600 mg/day: A common total daily dose across split-dose protocols. The 2024 review on ashwagandha plus meditation specifically identified both 250 mg/day and 600 mg/day arms showing significant cortisol decreases.
• Higher doses: Some trials have tested up to 1,000–1,250 mg/day, particularly for outcomes related to athletic performance and testosterone, but these higher doses are less represented in the stress biomarker literature specifically.

Root Versus Leaf Versus Full-Spectrum Extracts

As noted in the KSM-66 section, the extract type matters. The majority of stress biomarker trials have used standardized root extracts. Trials using leaf-based extracts (such as Sensoril/Shoden, which uses root and leaf) show comparable cortisol effects in some studies but different withanolide profiles. Making direct comparisons across trials using different extracts requires caution.

Standardization Markers

Most trial extracts are standardized to withanolide content, typically reported as a percentage:

• KSM-66: ≥5% withanolides
• Sensoril: ≥10% withanolides (including withanosides)
• Generic extracts: Variable, often 1.5–5%

Higher withanolide percentage does not automatically mean greater efficacy because the type of withanolide and the ratio among active constituents also matter. This is why extract-specific clinical data is more informative than dose comparisons across non-standardized preparations.

---

Does Ashwagandha Work Better In Stressed Adults?

This is one of the most scientifically interesting questions in the ashwagandha biomarker literature, and the evidence points toward a clear answer: yes, the effect on stress biomarkers is substantially more pronounced in populations with objectively elevated baseline stress indicators.

The Baseline Dependency Pattern

Across the ashwagandha biomarker study literature, a consistent pattern emerges: participants who enter trials with higher baseline cortisol, higher PSS scores, or more documented stressors (occupational, caregiving, academic) show larger absolute and relative cortisol reductions than those with normal baseline cortisol.

This is consistent with the adaptogen hypothesis. If ashwagandha's primary action is to normalize HPA axis feedback rather than simply suppress adrenocortical output, then its effect would be most visible when the axis is dysregulated — i.e., when baseline cortisol is elevated and feedback efficiency is reduced.

Implications For Study Design And Interpretation

Many of the trials showing robust cortisol reduction used explicit inclusion criteria for chronic stress — either through self-report questionnaire scores above a threshold, or by requiring elevated baseline cortisol as an entry criterion. When trials include normocortisolemic participants, the apparent effect size shrinks, not necessarily because the intervention is less effective but because there is less room for improvement.

The 2026 three-arm trial that failed to show statistically significant between-group cortisol differences may partially reflect this phenomenon — if the enrolled population included participants across a wide range of baseline cortisol values, diluting the detectable signal.

Practical Implication

For the individual consumer or clinician, this means that the published evidence is most directly applicable to adults experiencing documented, ongoing stress — not to low-stress individuals seeking performance optimization. The expected effect in a normocortisolemic healthy adult is likely smaller and less consistent than the headline numbers from stressed-population trials suggest.

---

Individual trials tell important stories, but meta-analyses that pool data across multiple studies provide the most statistically powerful estimates of effect. The 2024–2026 period has seen meaningful updates to the meta-analytic literature on ashwagandha stress biomarkers.

The 2025 Systematic Review And Meta-Analysis

A systematic review and meta-analysis published in 2025 examined multiple randomized controlled trials of ashwagandha supplementation on cortisol and perceived stress. The pooled cortisol analysis reported a significant reduction of −1.16 µg/dL (95% CI: −1.64 to −0.69, P < 0.001) — a finding that crosses the threshold for statistical significance with a confidence interval that does not include zero, providing reasonably robust evidence of a real effect on serum cortisol.

Notably, the same meta-analysis found no significant effect on perceived stress overall when pooling all included trials. This is a counterintuitive finding given that many individual trials show both cortisol and stress scale improvements. The explanation likely involves heterogeneity across trials in population selection, stress measurement tools, and intervention duration — factors that reduce the pooled effect size when diverse studies are combined. It also raises the scientifically interesting possibility that cortisol reduction and subjective stress relief may sometimes be partially decoupled.

The 2026 BJPsych Open Meta-Analysis

A 2026 meta-analysis published in BJPsych Open — one of the top-ranking sources in the current literature — reported statistically significant reductions in both perceived stress and cortisol at 8 weeks, with pooled estimates of PSS μ = −4.88 and cortisol μ = −2.3626. The alignment of both subjective and biological outcomes in this analysis, focused on the 8-week timepoint, provides stronger evidence for clinical relevance than analyses pooling across all timepoints.

This meta-analysis is particularly noteworthy because BJPsych Open applies rigorous peer review standards and because the 8-week focus may have reduced heterogeneity by controlling for the timing variable that confounds multi-timepoint pooling.

The 2024 Review On Ashwagandha And Meditation

A 2024 article examining the combination of ashwagandha supplementation and meditation reported reductions in both PSS and serum cortisol in supplemented groups. Both the 250 mg/day and 600 mg/day arms showed significant cortisol decreases, with the combination approach potentially amplifying the effect through complementary mechanisms — reduced HPA activation from meditation practice combined with enhanced feedback sensitivity from the supplement.

The NIH Office Of Dietary Supplements Update

The NIH Office of Dietary Supplements updated its health professional fact sheet on ashwagandha in 2025, summarizing the current evidence as supporting reductions in stress, anxiety, sleeplessness, fatigue, and serum cortisol versus placebo. This represents an official federal health authority acknowledgment of the cortisol and stress biomarker evidence — a meaningful signal given the NIH ODS's typically conservative standard for evidence-based claims.

The 2025 Adaptogenic Herb Review

A 2025 review on ashwagandha as an adaptogenic herb specifically summarized the 64-participant trial showing a 27.9% cortisol reduction after 60 days, contextualizing it within the broader evidence base for HPA axis modulation by botanical adaptogens. The review positioned this as among the strongest individual-trial evidence for cortisol effects of any single adaptogenic compound.

Overall Assessment Of The Meta-Analytic Picture

Across the 2024–2026 meta-analyses and systematic reviews, the evidence converges on several conclusions:

1. Serum cortisol is consistently reduced by ashwagandha supplementation, with pooled estimates ranging from approximately −1.2 to −2.4 µg/dL depending on the included trials and timepoints.
2. The effect on perceived stress is significant in some meta-analyses (particularly the 2026 BJPsych Open analysis) but not all, suggesting population heterogeneity as a key moderator.
3. Eight weeks appears to be the inflection point at which both hormonal and subjective effects are most robustly detectable.
4. KSM-66 stress markers data from standardized root extract trials provides the most internally consistent evidence base.

---

Safety, Side Effects, And Long-Term Biomarker Monitoring

Any discussion of ashwagandha biomarker effects would be incomplete without addressing the safety profile, particularly because some side effects — when they occur — are themselves detectable through biomarker changes.

Short-Term Safety Profile

In the clinical trials reviewed above, ashwagandha was generally well tolerated at doses of 300–600 mg/day for 60–90 days. The most commonly reported adverse events were:

• Gastrointestinal discomfort (nausea, loose stools, stomach upset) — more common at higher doses and typically mild to moderate
• Drowsiness — particularly in evening dosing protocols, which may be partially attributable to GABAergic activity
• Headache — reported in some trials at low frequencies

Discontinuation rates due to adverse events in most trials were comparable between ashwagandha and placebo groups, suggesting that many reported symptoms may be coincidental rather than causally related to the supplement.

Liver Safety: An Important Biomarker Consideration

A small number of case reports in the literature have raised concerns about hepatotoxicity with ashwagandha use, typically involving liver enzyme elevations (ALT, AST) that resolved after discontinuation. The absolute incidence appears low, but the possibility is important enough that clinicians advising patients on ashwagandha use should consider baseline liver function monitoring and follow-up in individuals with preexisting hepatic conditions or concurrent use of hepatotoxic medications.

From a biomarker standpoint, this means that individuals using ashwagandha for stress biomarker management might reasonably include periodic liver function panels in their monitoring protocol.

Thyroid Biomarker Interactions

Ashwagandha has been shown in some trials to modestly increase thyroid hormone levels (TSH, T3, T4). For individuals with hypothyroidism or those taking thyroid hormone replacement, this interaction can alter medication requirements and thyroid biomarkers. Thyroid function testing is advisable in long-term users, particularly those with known thyroid conditions.

Safety In Pregnancy And Special Populations

The NIH ODS fact sheet explicitly notes that ashwagandha should be avoided in pregnancy due to evidence of potential abortifacient effects at high doses. Safety in pediatric populations, individuals with autoimmune conditions, and those taking immunosuppressive medications has not been adequately established.

Long-Term Biomarker Monitoring Considerations

For individuals using ashwagandha over extended periods (beyond 90 days), a reasonable biomarker monitoring approach might include:

• Serum cortisol (morning fasting) at baseline, 8 weeks, and every 3–6 months
• Liver function panel (ALT, AST, bilirubin) at baseline and every 3–6 months
• Thyroid panel (TSH, free T4) at baseline and annually or more frequently if symptomatic
• hsCRP as part of a cardiovascular risk panel if inflammatory effects are a primary motivation for use

---

Practical Takeaways For Interpreting The Evidence

Having reviewed the full scope of ashwagandha and stress biomarker research, several practical principles emerge for anyone trying to make sense of this literature.

1. The Cortisol Evidence Is Real But Context-Dependent

The serum cortisol reductions documented in ashwagandha trials are statistically significant in most individual studies and confirmed by multiple meta-analyses. The effect is real. But it is most pronounced in adults with elevated baseline cortisol and documented chronic stress. Extrapolating these findings to healthy, normocortisolemic individuals requires caution.

2. KSM-66 Has The Strongest Standardized Evidence Base

Among the ashwagandha preparations studied for KSM-66 stress markers and KSM-66 cortisol biomarker effects, the standardized root extract approach has generated the most internally consistent data. When evaluating any specific product for stress biomarker effects, verifying that it uses a standardized extract with documented clinical trial evidence is more informative than total milligram dose alone.

3. Inflammatory Markers Are Promising But Understudied

The ashwagandha CRP and ashwagandha hsCRP evidence is directionally positive but based on fewer and smaller trials than the cortisol data. Ashwagandha inflammatory markers research is a growth area, and larger trials with inflammation as a primary endpoint are needed before strong clinical claims can be made.

4. Ashwagandha HRV Effects Are An Emerging Signal

The ashwagandha HRV literature is small but consistent in direction. As wearable technology makes continuous HRV monitoring more accessible, this biomarker will likely become more prominent in future ashwagandha biomarker study designs.

5. Eight Weeks Is The Evidence-Supported Minimum

Based on the ashwagandha stress biomarkers literature, eight weeks at an adequate dose appears to be the minimum duration at which meaningful cortisol and perceived stress changes are robustly detectable. Shorter trials and shorter personal trials may underestimate the potential effect.

6. Subjective And Objective Outcomes Do Not Always Align

The 2025 meta-analysis finding of significant cortisol reduction without significant perceived stress reduction is a reminder that biological and subjective outcomes are related but not identical. An individual might show cortisol normalization on a blood panel without a proportionate change in how stressed they feel — or vice versa. Using multiple measurement approaches, both biological and functional, provides a more complete picture.

---

---

Frequently Asked Questions

Does ashwagandha lower cortisol?

Yes, the clinical evidence supports this. Multiple randomized controlled trials and meta-analyses have documented statistically significant reductions in serum cortisol with ashwagandha supplementation, primarily at doses of 300–600 mg/day over 8 weeks or more. The 2025 meta-analysis reported a pooled reduction of −1.16 µg/dL (P < 0.001), and the 2026 BJPsych Open meta-analysis reported a mean cortisol reduction of approximately −2.36 µg/dL at 8 weeks with statistical significance. The effect is most pronounced in adults with elevated baseline cortisol.

How fast does ashwagandha reduce stress biomarkers?

Based on available trial data, measurable changes in serum cortisol are most consistently documented at 8 weeks. Some trials report directional improvements at 4 weeks, but these are less consistently significant. HRV improvements may appear somewhat earlier, while CRP changes may require longer intervention periods. A minimum 8-week trial at an adequate dose is recommended before evaluating personal response.

What dose was used in clinical trials?

The most commonly studied doses in ashwagandha stress biomarker research are 300 mg/day and 600 mg/day of standardized root extract. The 64-adult trial showing 27.9% cortisol reduction used 300 mg twice daily (600 mg total). A 2024 review documented significant cortisol reductions at both 250 mg/day and 600 mg/day. Doses below 250 mg/day have not been well-studied for cortisol effects.

Is the evidence stronger for cortisol or for perceived stress scores?

The cortisol evidence is more consistently statistically significant across meta-analyses. The 2025 systematic review found significant cortisol reduction but no significant effect on perceived stress overall. The 2026 BJPsych Open meta-analysis found both to be significant at 8 weeks. Overall, cortisol effects are more robustly supported across the pooled literature, though both outcomes are documented in most individual trials.

Are there side effects or safety concerns with long-term use?

Short-term use at clinical trial doses (300–600 mg/day for 60–90 days) is generally well tolerated. The primary concerns are gastrointestinal discomfort, potential liver enzyme elevation (rare case reports), and possible thyroid hormone interactions. Pregnancy is a contraindication. Long-term users should consider periodic monitoring of liver function, thyroid hormones, and cortisol to assess ongoing response and safety.

Does ashwagandha work better in stressed adults than in healthy adults?

Yes. The clinical literature consistently shows larger cortisol reductions in participants with elevated baseline cortisol and documented chronic stress compared to normocortisolemic adults. This is consistent with the adaptogen framework. The headline cortisol reduction percentages in published trials predominantly reflect stressed populations and should not be directly applied to expectations in low-stress healthy adults.

Which extract types have been studied most?

Standardized root extracts — particularly KSM-66 (≥5% withanolides) and Sensoril (≥10% withanolides, root and leaf combined) — have the most robust clinical evidence for stress biomarker effects. Generic or non-standardized ashwagandha preparations have variable withanolide content and less direct clinical evidence. For biomarker-specific outcomes, extracts with documented clinical trial data using that specific preparation provide the most reliable predictions.

Can ashwagandha change other biomarkers besides cortisol?

Yes. The clinical literature documents effects on DHEA-S, thyroid hormones (TSH, T3, T4), inflammatory markers (CRP, hsCRP), oxidative stress markers (MDA, SOD), lipid panels, and testosterone in some populations. The evidence base is strongest for cortisol. Ashwagandha HRV effects have been reported in multiple studies, positioning it as a functionally relevant biomarker alongside the hormonal measures. The breadth of biomarker effects is consistent with ashwagandha's proposed multi-pathway mechanism of action.

---

Conclusion

The science of ashwagandha and stress biomarker research has matured substantially in the past five years. What was once primarily anecdotal or based on small, low-quality trials is now supported by a body of randomized controlled trials, systematic reviews, and meta-analyses that meet modern evidence standards — with the NIH ODS acknowledging the cortisol and stress evidence in its 2025 health professional fact sheet.

The most robust finding is clear: standardized ashwagandha root extract at 300–600 mg/day for 8 weeks reduces serum cortisol in adults with documented chronic stress. The effect size is clinically meaningful (approximately 20–30% reduction from elevated baseline in high-quality trials), statistically significant in meta-analyses (pooled estimates of −1.16 to −2.36 µg/dL), and accompanied by improvements in validated psychometric stress scales in most but not all analyses.

The evidence for ashwagandha CRP, ashwagandha hsCRP, and broader ashwagandha inflammatory markers is directionally positive but requires larger, inflammation-focused trials to characterize properly. Ashwagandha HRV effects represent an exciting emerging area that wearable technology will help clarify in coming years.

The limitations are real and worth respecting: effect sizes are smaller in non-stressed populations, some larger trials have failed to achieve between-group statistical significance for cortisol, and the mechanism remains incompletely understood. These limitations do not invalidate the evidence — they contextualize it.

For anyone approaching this topic from a biomarker science perspective, the most important takeaway is that the ashwagandha stress biomarkers evidence is now robust enough to take seriously and nuanced enough to require careful population-specific interpretation. The research is ongoing, and the 2024–2026 publications reviewed here suggest that the field is asking increasingly sophisticated questions — moving beyond "does it work?" toward "in whom, at what dose, through what biological mechanisms, and detectable by which markers?"

Those are the right questions, and the science is beginning to answer them.

---

This post is for educational and informational purposes only. It does not constitute medical advice. Consult a qualified healthcare professional before beginning any supplement regimen, particularly if you have existing medical conditions, take prescription medications, or are pregnant or breastfeeding.